natgillin/translations-raw huggingface dataset:
eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes – these may be signs of glaucoma. irregular heartbeat.
bolečina ali ščemenje v očeh, začasno zamegljen vid, zaznavanje svetlobnih ali živobarvnih kolobarjev okrog luči v povezavi s pordelostjo oči - to so lahko znaki glavkoma; nepravilno bitje srca.
eye pain or infection, blurred vision, dry or teary eyes, changes in hearing/loss of hearing, ringing in ears,
boleče ali vnete oči, zamegljen vid, suhe ali solzne oči, sprememba sluha/izguba sluha, zvonjenje v ušesih,
eye pain or redness, pain, itching of the eyelids
boleče ali rdeče oči, bolečina, srbenje vek
Eye pain,
bolečine v očeh,
eye pain, eye irritation, dry eye, abnormal sensation in eyes
očesna bolečina, draženje očesa, suho oko, nenormalen občutek v očeh
eye pain, eye pruritus, conjunctival hyperaemia
očesna bolečina, očesni pruritus, hiperemija veznice
Eye pain, eye swelling
bolečine v očesu, otekanje očesa
Eye pain, Photophobia,
bolečine v očeh,
Eye pain, Photophobia,
očesna hiperemija,
Eye pressure is measured in ‘millimetres of mercury’ (mmHg).
Očesni tlak se meri v milimetrih živega srebra (mmHg).
Eye problems (uncommon), such as pain, redness, watery eyes, light sensitivity, changes in vision or ingrowing eyelashes.
Težave z očmi (občasne), npr. bolečine, pordelost, solzenje, občutljivost na svetlobo, spremembe vida ali vraščanje trepalnic.
Eye problems during treatment with ANORO
Težave z očmi med zdravljenjem z zdravilom ANORO
Eye problems during treatment with Incruse
Težave z očmi med zdravljenjem z zdravilom Incruse
Eye problems during treatment with LAVENTAIR
Težave z očmi med zdravljenjem z zdravilom LAVENTAIR
Eye problems including blurred or reduced vision, puffy eyes or sties
težave z očmi, vključno z zamegljenim vidom ali slabovidnostjo, otečene oči ali ječmen na očesu
Eye problems including blurred or reduced vision, puffy eyes or sties
težave z očmi, vključno z zamegljenim vidom ali slabovidnostjo, otečene oči ali ječmen na očesu,
eye problems including changes in vision, damage to the retina, obstruction of the retinal artery, inflammation of the optic nerve, swelling of the eye,
očesne težave vključno s spremembami vida, poškodbe mrežnice, obstrukcija mrežnične arterije, vnetje vidnega živca, otekanje oči,
eye problems including damage to the retina, obstruction of the retinal artery, inflammation of the optic nerve, swelling of the eye and cotton wool spots (white deposits on the retina),
očesne težave, vključno z okvaro mrežnice, zamašitvijo mrežnične arterije, vnetjem očesnega živca, otekanjem očesa in belimi lisami na mrežnici (na mrežnici se pojavijo bele usedline),
eye problems including: blurred and less clear vision, cloudy lens in the eye (cataract), spots or deposits in eye (vitreous floaters), dry eye, itchy eye, yellowing of the whites of the eye or skin
težave z očmi, med katerimi so lahko: zamegljen in nejasen vid, motnost očesne leče (siva mrena, katarakta), pikice ali motnjave v očesu (delci v steklovini), suhe oči, skeleče oči, porumenelost beločnic ali kože
eye problems, including blurred and less clear vision
težave z očmi, vključno z zamegljenim vidom in zmanjšano ostrino vida
Eye problems, including red eyes and infections
težave z očmi, vključno z rdečimi očmi in okužbami
Eye problems, including red eyes and infections
težave z očmi, vključno z rdečimi očmi in okužbami,
Eye problems, including red eyes and infections
težave z očmi, vključno z rdečino in okužbami
eye problems, including: cloudy lens in the eye (cataract), dry eye, small yellow deposits in the retina, yellowing of the whites of the eye
težave z očmi vključujejo: motnost očesne leče (katarakta), suhe oči, majhne rumene obloge v mrežnici, rumeno obarvanje očesnih beločnic
eye pruritus, ocular hyperaemia
očesni pruritus, očesna hiperemija
Eye reactions
Motnje vida
Eye reactions
Reakcije na očeh
Eye reactions: A big change in your blood sugar control (getting better or worse) can disturb your vision.
Očesne reakcije – velika sprememba urejenosti krvnega sladkorja (izboljšanje ali poslabšanje) lahko povzroči moti vid.
eye redness
pordelost očesa,
eye redness
pordelost oči
eye redness and irritation
pordelost in draženje očesa
eye redness or infection
pordelost ali okužba oči
eye strain
naprezanje očesa
eye surface problems
težave na površju očesa;
Eye swelling
Opuch oka
Eye swelling
otekanje očesa
Eye swelling
otekanje oči
Eye swelling
otekle oči
Eye swelling was evaluated in a review of 30 cases.
Otekanje očesa je bilo ocenjeno pri obravnavi 30 primerov.
Eye swelling*, Vision abnormal*, Conjunctivitis*
zatekanje očesa*, nenormalen vid*, konjuktivitis
Eye swelling,
astenopija,
Eye swelling,
oteklost oči,
eye swelling, and abnormal vision.
otekanje oči sprememba vida
Eye: eye problems, increased or decreased tearing discomfort, vision problems, serious illness with blistering of the eyes, wearing away of the surface “skin” of the eye (corneal erosion)
Oči: očesne težave, neprijeten občutek pri močnejšem ali šibkejšem solzenju, težave z vidom, huda bolezen z mehurčki na očeh, izjedanje površinske plasti očesa (erozija roženice).
Eye: eye problems, increased or decreased tearing discomfort, vision problems, serious illness with blistering of the eyes, wearing away of the surface “skin” of the eye (corneal erosion).
Oči: očesne težave, neprijeten občutek pri močnejšem ali šibkejšem solzenju, težave z vidom, huda bolezen z mehurčki na očeh, izjedanje površinske plasti očesa (erozija roženice).
Eye: itchy and red eyes, allergic reactions in eyes, drooping upper eyelid
Oči: srbeče in rdeče oči, alergijske reakcije pri očeh, povešenje zgornje veke
Eyelash changes
premembe trepalnic,
eyelash darkening, blepharospasm, retinal haemorrhage, uveitis, periorbital erythema.
temnenje trepalnic, blefarospazem, krvavitev iz mrežnice, uveitis, periorbitalni eritem
Eyelash discolouration
sprememba barve trepalnic
Eyelash trichomegaly
Trihomegalija trepalnic
eyelashes falling out (madarosis) changes in blood tests, which include increased values in liver tests or increased values in creatine phosphokinase (a protein mainly from muscle).
izpadanje trepalnic (madaroza), spremembe v krvnih preiskavah, ki vključujejo zvišane vrednosti jetrnih testov ali zvišane vrednosti kreatin-fosfokinaze (beljakovine, ki se večinoma nahaja v mišicah).
Eyelid irritation Keratitis1
draženje vek keratitis1
eyelid irritation swelling of the front layer of the eyeball (cornea)
draženje veke oteklina sprednje plasti zrkla (roženice)
Eyelid oedema
edem očesne veke
Eyelid oedema
edem vek
Eyelid oedema
edem veke
Eyelid oedema, lacrimation increased, conjunctival haemorrhage, conjunctivitis, dry eye, blurred vision
edem vek, povečano solzenje, veznična krvavitev, vnetje veznice, suhe oči, zamegljen vid
eyelid pain
bolečina v veki,
eyelid pruritus
pruritus vek
Eyelid shrinking, moving away from surface of the eye
krčenje veke oz. odmik veke od površine očesa,
Eyelid shrinking, moving away from surface of the eye
krčenje veke oz. veka se odmakne od površine očesa,
eyelid swelling
otekle veke
eyelid swelling caused by excess fluid
otekanje vek zaradi odvečne tekočine
eyelid swelling; lip swelling.
oteklost vek, oteklost ustnic.
Eyelid twitching
trzanje veke,
Eyes and mucous membranes
Oči in sluznice
Eyes appear sunken
videz udrtih oči,
Eyes appear sunken
videz udrtih oči, suhe oči.
Eyes disorders
Očesne bolezni
eyes feel sticky, gritty
lepljiv ali umazan občutek v očeh,
Eyes or ears: dry eyes; ringing in the ears; changes in your vision
Oči in ušesa: suhost oči, zvonjenje v ušesih, spremembe vida
Eyes or ears: ear ache
Oči in ušesa: bolečina v ušesu
Eyes or ears: pink eye; eye pain; deafness; trouble hearing; swelling around the eyelid; increased tearing; fluid draining from the ear or eye; abnormal feeling around the eye, red patch on the white of the eye; yellowing of the white part of the eyes or of the skin
Oči in ušesa: pordelo oko, bolečine v očeh, gluhost, naglušnost, oteklost okrog vek, močnejše solzenje, tekoč izcedek iz ušesa ali očesa, nenormalen občutek okrog očesa, rdeče lise na očesni beločnici, porumenelost očesne beločnice ali kože
Eyes tearing
olzenje
Eyes with Anterior Chamber Intraocular Lens (ACIOL), iris or transscleral fixated intraocular lens and ruptured posterior lens capsule.
Oko z umetno lečo v sprednjem prekatu (ACIOL - Anterior Chamber Intraocular Lens), s pritrjeno umetno lečo na šarenico ali skozi beločnico in raztrgano posteriorno kapsulo leče.
Eyesight problems such as blurred vision.
težave z vidom, npr. zamegljen vid
Eyestrain, inner ear problems.
naprezanje oči, težave z notranjim ušesom
Eylea
zdravilo Eylea
Eylea 2mg Q4 (N = 91)
4 tedne (N = 91)
Eylea 2mg Q8 (N = 91) D)
zdravilo Eylea 2 mg, vsakih
Eylea 2mg Q8 (N = 91)D)
zdravilo Eylea 2 mg, vsakih
Eylea 40 mg/ml solution for injection Aflibercept
Eylea 40 mg/ml raztopina za injiciranje aflibercept
Eylea 40 mg/ml solution for injection in a pre-filled syringe
Eylea 40 mg/ml raztopina za injiciranje v napolnjeni injekcijski brizgi aflibercept
Eylea 40 mg/ml solution for injection in a vial
Eylea 40 mg/ml raztopina za injiciranje v viali aflibercept
Eylea 40 mg/ml solution for injection in a vial Aflibercept
Eylea 40 mg/ml raztopina za injiciranje v viali aflibercept
Eylea 40 mg/ml solution for injection in a vial.
Eylea 40 mg/ml raztopina za injiciranje v viali
Eylea 40 mg/ml solution for injection in pre-filled syringe
Eylea 40 mg/ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Eylea 40 mg/ml solution for injection in pre-filled syringe Aflibercept
Eylea 40 mg/ml raztopina za injiciranje v napolnjeni injekcijski brizgi aflibercept
Eylea F)
zdravilo EyleaF 2 mg
Eylea G)
zdravilo EyleaG 2 mg
Eylea is a medicine that contains the active substance aflibercept.
Eylea je zdravilo, ki vsebuje zdravilno učinkovino aflibercept.
Eylea is a solution for injection (injection) in a pre-filled syringe (3.6 mg/90 microlitres).
Zdravilo Eylea je raztopina za injiciranje (injekcija) v napolnjeni injekcijski brizgi (3,6 mg/90 mikrolitrov).
Eylea is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), visual impairment due to diabetic macular oedema (DME) (see section 5.1), visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).
Zdravilo Eylea je indicirano pri odraslih za zdravljenje neovaskularne (vlažne) starostne degeneracije makule (AMD - Age-related Macular Degeneration) (glejte poglavje 5.1), okvare vida zaradi makularnega edema, ki nastane kot posledica zapore mrežnične vene (zapore veje mrežnične vene (BRVO - Branch Retinal Vein Occlussion) ali zapore centralne mrežnične vene (CRVO - Central Retinal Vein Occlusion)) (glejte poglavje 5.1), okvare vida zaradi diabetičnega makularnega edema (DME - Diabetic Macular Oedema) (glejte poglavje 5.1), okvare vida zaradi miopične horoidalne neovaskularizacije (miopične CNV - myopic Choroidal Neovascularisation) (glejte poglavje 5.1).
Eylea is not recommended during breast-feeding as it is not known whether Eylea passes into human milk.
Uporaba zdravila Eylea se ne priporoča med dojenjem, saj ni znano, ali zdravilo Eylea prehaja v materino mleko.
Eylea is used to treat adults with:
Zdravilo Eylea se uporablja za zdravljenje odraslih z:
Eylea must be given as an intravitreal injection (injection into the vitreous humour, the jelly-like fluid in the eye) by a qualified doctor who is experienced in giving intravitreal injections.
Zdravilo Eylea mora kot intravitrealno injekcijo (injekcijo v steklovino, želatini podobno tekočino v očesu) injicirati ustrezno usposobljen zdravnik, ki ima izkušnje z dajanjem intravitrealnih injekcij.
Eylea must not be used in patients who have or are thought to have ocular or periocular infections (infections in or around the eyes), or in patients who have severe inflammation inside the eye.
Zdravilo Eylea se ne sme uporabljati pri bolnikih, ki imajo ali utegnejo imeti okularno ali periokularno okužbo (okužbo v očesu ali v okolici očesa), in tisti, ki imajo hudo vnetje v očesu.
Eylea should not be used in pregnancy unless the potential benefit outweighs the potential risk to the foetus (see section 4.6).
Zdravila Eylea se ne sme uporabljati med nosečnostjo, razen če so možne koristi večje od možnega tveganja za plod (glejte poglavje 4.6).
Eylea treatment is initiated with one injection per month for three consecutive doses, followed by one injection every two months.
Zdravljenje z zdravilom Eylea se začne z eno injekcijo na mesec, tri zaporedne mesece, nato pa nadaljuje z eno injekcijo vsaka dva meseca.
Eylea was investigated in two main studies involving a total of around 2,400 patients with the wet form of AMD.
Zdravilo Eylea je bilo raziskano v dveh glavnih študijah, v kateri je bilo vključenih približno 2 400 bolnikov z vlažno obliko starostne degeneracije makule.
ezetimibe and statins , such as atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin – used for high cholesterol,
ezetimib in statine, kot so atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin – uporabljajo se za zdravljenje zvišanega holesterola,
F - 75003 Paris France
F - 75003 Paris Francija
F - 75008 Paris France
F - 75008 Paris Francija
F - 75008 Paris France
F – 75008 Paris Francija
f 48 weeks of double-blind adefovir dipivoxil followed by 96 weeks open-label tenofovir disoproxil fumarate. g Figures presented are cumulative percentages based upon a Kaplan Meier analysis including data collected after the addition of emtricitabine to open-label tenofovir disoproxil fumarate (KM-ITT).
f 48-tedensko dvojno slepo zdravljenje z dipivoksiladefoviratom, ki mu sledi 96-tedensko odprto zdravljenje z dizoproksiltenofovirijevim fumaratom. g Prikazane številke so kumulativni odstotki na podlagi Kaplan-Meierjeve analize, vključno s podatki, zbranimi po dodajanju emtricitabina k odprtemu zdravljenju z dizoproksiltenofovirijevim fumaratom (KM–ITT).
f Include all CR+CRu, by IRC, bone marrow and LDH.
f Vključuje vse CR+CRu, IRC, kostni mozeg in LDH.
f including heart rate increased, sinus tachycardia
f vključno s povečanim srčnim utripom, sinusno tahikardijo
F See corresponding subsections below for events in the dapagliflozin programme.
F Za dogodke v programu dapagliflozina glejte ustrezna podpoglavja v nadaljevanju.
f the pre-filled syringe does not release from the tray, gently press on the back of tray.
Če se napolnjena injekcijska brizga ne sprosti iz pretisnega omota, previdno pritisnite na njegovo zadnjo stran.
F – 75008 Paris France
F – 75008 Paris Francija
F – 75008 Paris France
F – 75008 Pariz Francija
F) A confidence interval lying entirely above -10% indicates a non-inferiority of Eylea to ranibizumab
F) Interval zaupanja, ki je v celoti nad -10 %, kaže na neinferiornost zdravila Eylea v primerjavi z ranibizumabom
F) Difference and 95% CI are calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for country (country designations)
F) Razlika in 95 % interval zaupanja (IZ) se izračunata s pomočjo Cochran-Mantel-Haenszelovega (CMH) testa, prilagojenega za državo (country designations).
F) In COPERNICUS study, both control group and Eylea 2mg patients received Eylea 2 mg on an as-needed basis as frequently as every 4 weeks starting from Week 52 to Week 96; patients had mandatory quarterly visits but may have been seen as frequently as every 4 weeks if necessary.
F) V študiji COPERNICUS so bolniki v kontrolni skupini in bolniki zdravljeni z zdravilom Eylea 2 mg, od 52. do 96. tedna, prejemali zdravilo Eylea 2 mg glede na potrebe vsake 4 tedne; bolniki so imeli obvezne preglede vsake tri mesece oziroma so na preglede prihajali pogosteje, tudi vsake 4 tedne, če je bilo potrebno.
F) Nominal p-value
F) Nominalna vrednost p
F-07100 Annonay France
F-07100 Annonay Francija
F-14200 Hérouville St Clair France
F-14200 Hérouville St Clair Francija
F-27460 Igoville France
F-27460 Igoville Francija
F-28000 Chartres France
F-28000 Chartres Francija
F-31057 Toulouse Cedex France
F - 31057 Toulouse Cedex Francija
F-33565 Carbon Blanc Cedex - France
F-33565 Carbon Blanc Cedex - Francija
F-33565 Carbon Blanc Cedex France
F-33565 Carbon Blanc Cedex Francija
F-45400 Semoy France
F-54400 Semoy Francija
F-49000 Angers France
F-49000 Angers Francija
F-64320 Idron France
F-64320 Idron Francija
F-68330 Huningue Cedex France
F-68330 Huningue Cedex Francija
F-68330 Huningue France
F-68330 Huningue Cedex Francija
F-68330 Huningue France
F-68330 Huningue Francija
F-69 800 Saint Priest France
F-69 800 Saint Priest Francija
F-69800 SAINT PRIEST FRANCE
F-69800 SAINT PRIEST FRANCIJA
F-75003 Paris France
F-75003 Pariz Francija
F-75008 Paris - France
F-75008 Paris - Francija
F-75008 Paris - France
F-75008 Paris – Francija
F-75008 Paris France
F-75008 Paris Francija
F-75008 Paris – France
F-75008 Paris – Francija
F-76960 Notre Dame de Bondeville France
76960 Notre Dame de Bondeville Francija
F-76960 Notre Dame de Bondeville France
F-76960 Notre Dame de Bondeville Francija
F-91192 GIF-SUR-YVETTE Cedex
F-F-91192 GIF-SUR-YVETTE Cedex
F-92100 Boulogne France
F-92100 Boulogne Francija
F-92654 Boulogne Billancourt Cedex France
F-92654 Boulogne Billancourt Cedex Francija
F-92654 Boulogne-Billancourt cedex France
F-92654 Boulogne-Billancourt cedex Francija
F. Stability
F. STABILNOST
F396Y
P389L
F: +39 031 5373241 info@gentium.it
Faks: +39 031 5373241 info@gentium.it
FABLYN 500 microgram film-coated tablets lasofoxifene
FABLYN 500 mikrogramov filmsko obložene tablete lasofoksifen
FABLYN 500 microgram film-coated tablets.
FABLYN 500 mikrogramov filmsko obložene tablete
FABLYN causes morphologic changes, particularly the cystic atrophy of endometrium.
Zdravilo FABLYN povzroča morfološke spremembe, še posebno cistično atrofijo endometrija.
FABLYN has no known influence on the ability to drive and use machines.
Ni znano, da bi zdravilo FABLYN vplivalo na sposobnost upravljanja vozil in strojev.
FABLYN increases risk of venous thromboembolism (VTE).
Zdravilo FABLYN poveča tveganje za pojav venskih trombemboličnih dogodkov (VTE-venous thromboembolism).
Fablyn is intended for long-term use.
Zdravilo Fablyn je predvideno za dolgotrajno uporabo.
Fablyn is only for use in women who have been through the menopause, so it must not be used in women who could become pregnant, or women who are pregnant or breast- feeding.
Zdravilo Fablyn je namenjeno le ženskam po menopavzi, zato ga ne smejo uporabljati ženske, ki bi lahko zanosile, nosečnice ali ženske, ki dojijo.
FABLYN must not be taken by women of child- bearing potential (see section 4.3).
Ženske v rodni dobi zdravila FABLYN ne smejo jemati (glejte poglavje 4.3).
FABLYN must not be taken during lactation (see section 4.3).
Doječe matere zdravila FABLYN ne smejo jemati (glejte poglavje 4.3).
FABLYN tablets are triangular, peach coloured, film-coated tablets marked with “Pfizer” on one side and “OPR 05” on the other.
Tablete FABLYN so trikotne filmsko obložene tablete breskove barve z vtisnjenim napisom “Pfizer” na eni strani in “OPR 05” na drugi strani.
Fabrazyme 35 mg powder for concentrate for solution for infusion
Fabrazyme 35 mg, prašek za koncentrat za raztopino za infundiranje
Fabrazyme 5 mg powder for concentrate for solution for infusion
Fabrazyme 5 mg, prašek za koncentrat za raztopino za infundiranje
Fabrazyme agalsidase beta
Fabrazyme agalzidaza beta
Fabrazyme contains the active substance agalsidase beta and is used as enzyme replacement therapy in Fabry disease, where the level of -galactosidase enzyme activity is absent or lower than normal.
Fabrazyme vsebuje zdravilno učinkovino agalzidaza beta in se uporablja kot encimska nadomestna terapija pri Fabryjevi bolezni, pri kateri bodisi ni encima α-galaktozidaze, ali pa je količina tega encima manjša od normalne.
Fabrazyme is given through a drip into a vein (by intravenous infusion).
Zdravilo Fabrazyme se daje skozi kapalko v veno (v obliki intravenske infuzije).
Fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.
Fabrazyme je indiciran za uporabo v obliki dolgoročne encimske nadomestne terapije pri bolnikih s potrjeno diagnozo Fabryjeve bolezni.
Fabrazyme may have a minor influence on the ability to drive or use machines on the day of Fabrazyme administration because dizziness, somnolence, vertigo and syncope may occur (see section 4.8).
Zdravilo Fabrazyme lahko ima blag vpliv na sposobnost vožnje in upravljanja s stroji na dan dajanja zdravila Fabrazyme, ker se lahko pojavijo omotica, zaspanost, vrtoglavica in sinkopa (glejte poglavje 4.8).
Fabrazyme pharmacokinetics was also evaluated in 15 paediatric patients (8.5 to 16 years old weighing 27.1 to 64.9 kg).
Farmakokinetika zdravila Fabrazyme je bila ocenjena tudi pri 15 pediatričnih bolnikih (starih od 8,5 do 16 let s telesno maso od 27,1 do 64,9 kg).
Fabrazyme should not be administered with chloroquine, amiodarone, benoquin or gentamycin due to a theoretical risk of inhibition of intra-cellular -galactosidase activity.
Zdravila Fabrazyme ne smete uporabljati sočasno s klorokvinom, amiodaronom, benokvinom ali gentamicinom zaradi teoretičnega tveganja za inhibicijo znotrajcelične aktivnosti α-galaktozidaze.
Fabry disease
Fabryjeva bolezen
Fabry Disease is a glycosphingolipid storage disorder that is caused by deficient activity of the lysosomal enzyme α-galactosidase A, resulting in accumulation of globotriaosylceramide (Gb3 or GL-3, also known as ceramidetrihexoside (CTH)), the glycosphingolipid substrate for this enzyme.
Fabryjeva bolezen je motnja skladiščenja glikosfingolipidov, ki jo povzroča premajhna aktivnost lizosomskega encima α-galaktozidaze A, kar povzroči kopičenje globotriaozilceramida (Gb3 ali GL-3, imenovanega tudi ceramidtriheksozid (CTH)), glikosfingolipidnega substrata tega encima.
Fabry disease is an inherited heterogeneous and multisystemic progressive disease, that affects both males and females.
Fabryjeva bolezen je dedna heterogena in multisistemska progresivna bolezen, ki prizadene tako moške kot ženske.
Fabry disease is caused by the lack of or a faulty enzyme called alpha-galactosidase A (α–Gal A).
Fabryjevo bolezen povzroča pomanjkanje ali nepravilno delovanje encima, imenovanega α- galaktozidaza A (α–Gal A).
Face
Obraz
Face oedema
edem obraza
face oedema
obrazni edem
Face oedema and angioedema*
edem obraza in angioedem
Face oedema*
edem obraza
Face oedema, oedema mouth
pireksija oteklost ustnic, edem vek edem obraza, edem ust
Face oedema, oedema peripheral
edem obraza, periferni edem
face oedema, oedemad,
edem obraza, edemd,
face oedema, oedemad,
kreatin
face oedema, oedemae,
edem obrazae,
Face oedema, Urticaria
angioedem, edem obraza, urtikarija
face or tongue; blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
mišicah obraza ali jezika; krvne strdke v venah (občasen neželeni učinek, ki lahko prizadene do 1 od 100 bolnikov), posebej v nogah (simptomi vključujejo otekanje, bolečino in rdečino na nogah), ki lahko po žilah potujejo v pljuča ter povzročijo bolečino v pljučih in težave z dihanjem.
Face swelling
otekanje obraza
face swelling
otekanje obraza,
face swelling
oteklost obraza
face, eyelids, lips or tongue
obraza, očesnih vek, ustnic ali jezika,
face, Purpura,
obraza, purpura,
Facial blushing or tiny broken capillaries
rdečica obraza ali pokanje drobnih kapilar
Facial malformations such as cleft lip, cleft palate, micrognathia and hypertelorism of the orbits;
malformacije obraza, kot so razcep ustnice, razcep neba, mikrognatija in orbitalni hipertelorizem,
Facial oedema
edem obraza
Facial oedema
Otečen obraz
facial oedema (swelling of the face)
edem obraza (otekanje obraza)
facial oedema (swelling of the face) associated with allergic reactions
edem obraza (otekanje obraza) povezan z alergijskimi reakcijami
facial oedema associated with allergic reactions;
edem obraza povezan z alergijskimi reakcijami;
Facial oedema, Chest pain2
otečen obraz, bolečina v prsih2